Merck & Co. (NYSE: MRK) reported first-quarter 2026 financial results on April 30, 2026 that beat revenue estimates and prompted management to raise its full-year outlook — even as a massive, one-time acquisition charge pushed the company to a GAAP net loss. Investors who look past the headline number will find a pharmaceutical giant whose core business is performing well and investing aggressively for what comes after its blockbuster cancer drug faces generic competition.
Q1 2026 By the Numbers
Total revenue reached $16.3 billion in the first quarter, a 5% increase year-over-year compared to $15.5 billion in Q1 2025, according to data from StockAnalysis. The top-line beat was driven by Merck’s oncology franchise, led by Keytruda (pembrolizumab) — the world’s best-selling cancer immunotherapy — alongside growing contributions from Winrevair (sotatercept), a pulmonary arterial hypertension drug approved in 2024.
On a GAAP basis, Merck posted a net loss of $4.2 billion, or $1.72 per diluted share, a sharp reversal from the $5.1 billion profit it earned in the year-ago quarter. The loss stems almost entirely from a single item: approximately $9 billion in acquisition-related charges recognized in the period, which caused research and development expenses to balloon to $12.6 billion — up from just $3.9 billion in Q4 2025 — per StockAnalysis quarterly data.
| Metric | Q1 2026 | Q1 2025 | YoY Change |
|---|---|---|---|
| Total Revenue | $16.3B | $15.5B | +5% |
| GAAP Net Income | –$4.2B | +$5.1B | –182% |
| GAAP EPS (Diluted) | –$1.72 | $2.01 | n/m |
| R&D Expense | $12.6B | ~$3.9B | +223% |
| Winrevair Revenue | $525M | — | New drug |
| Quarterly Dividend | $0.85/share | $0.81/share | +4.9% |
What Actually Drove the Reported Loss
The dramatic swing from a $5-billion profit to a $4-billion loss requires context. Merck recognized roughly $9 billion in acquisition-related charges during the quarter, primarily tied to in-process research and development (IPR&D) and upfront licensing costs from business development deals completed in early 2026, according to StockAnalysis. The largest disclosed deal was the $6.7 billion acquisition of Terns Pharmaceuticals, which brought a portfolio of clinical-stage obesity and metabolic disease candidates into Merck’s pipeline. Under GAAP accounting rules, these upfront payments are immediately expensed through R&D rather than amortized over time — a feature of pharmaceutical deal accounting that routinely produces large one-period losses even when the underlying business is growing.
On an adjusted (non-GAAP) basis — which strips out these charges — Merck’s operational profitability remained solid. The company’s 2026 consensus full-year EPS estimate of $5.09 per share (per analyst forecasts compiled by StockAnalysis) reflects the expectation that the bulk of deal-related charges landed in Q1, leaving Q2 through Q4 on a more normalized earnings trajectory.
Keytruda: Still Carrying the Franchise
Keytruda (pembrolizumab) remains the cornerstone of Merck’s revenue base. The PD-1 checkpoint inhibitor is approved for more than 40 cancer indications globally and consistently ranks as the world’s highest-grossing oncology product. Management noted that oncology performance drove Q1 growth, keeping Merck on pace with its full-year revenue forecast of approximately $67 billion, per analyst consensus data.
The drug’s long-term outlook carries a well-flagged risk: core Keytruda patents begin expiring in the United States in 2028, potentially opening the door to biosimilar competition. Merck has been candid about this “patent cliff” challenge, which is precisely why the Terns acquisition — targeting obesity drugs that could generate durable revenue in the 2030s — is strategically significant, even at a steep upfront cost.
Winrevair: The Emerging Growth Driver
Winrevair (sotatercept), Merck’s activin signaling inhibitor approved in March 2024 for pulmonary arterial hypertension (PAH), generated $525 million in revenue in Q1 2026, per Yahoo Finance. For context, PAH is a rare but life-threatening condition with a limited treatment landscape, and Winrevair became the first drug with a novel mechanism of action to be approved for the disease in over a decade.
Annualizing the Q1 pace puts Winrevair on track to exceed $2 billion in its first full year on the market — a strong commercial debut for a drug Merck acquired through its 2021 Acceleron Pharma deal. Analysts expect the drug’s label to expand and its revenue to compound significantly through 2028 and beyond, adding a second multibillion-dollar pillar alongside Keytruda.
AI and the Terns Deal: Merck Bets Big on What Comes Next
The quarter’s two largest investment announcements underscore where Merck’s leadership sees growth in the next decade. The $6.7 billion Terns Pharmaceuticals acquisition adds a pipeline of GLP-1 receptor agonist and other metabolic disease candidates — positioning Merck to participate in the obesity drug market alongside Eli Lilly and Novo Nordisk. That race has produced the fastest-growing therapeutic category in recent pharmaceutical history.
Separately, Merck announced a $1 billion strategic partnership with Google Cloud aimed at deploying artificial intelligence across drug discovery, manufacturing, and clinical trial design. While the commercialization timeline for AI-assisted R&D remains long, the partnership signals that Merck is moving beyond skepticism about AI’s near-term utility in drug development — a common stance as recently as 2023.
Guidance Raised Despite the Charges
Despite reporting a GAAP loss, Merck’s management raised its full-year 2026 revenue guidance, a signal of operational confidence. While Merck’s official guidance range was not publicly detailed at time of writing, analyst consensus compiled by StockAnalysis projects full-year 2026 revenue of $67.4 billion, up approximately 3.6% from fiscal 2025. The forward earnings picture improves sharply once Q1’s one-time charges roll off: consensus calls for full-year 2026 EPS of $5.09, then a rebound to $9.81 per share in 2027 — a 93% increase — as the business normalizes.
Stock Reaction and Analyst Sentiment
Merck shares fell 1.6% to close at $109.18 on April 30, with after-hours trading recovering slightly to $111.22, per StockAnalysis. The muted reaction — despite the headline loss — suggests the market had already priced in much of the acquisition-related charge. The stock remains roughly 4.8% ahead year-to-date, per Yahoo Finance.
Analyst sentiment is broadly constructive. Of 17 analysts tracked by StockAnalysis, the consensus rating is Buy, with 10 Buy or Strong Buy ratings and 7 Holds. The average price target stands at $125.59 — implying approximately 15% upside from the April 30 close — while UBS analyst Michael Yee recently raised his target from $130 to $145, citing confidence in Merck’s pipeline execution.
Merck also raised its quarterly dividend 4.9% to $0.85 per share ($3.40 annualized), maintaining a yield of approximately 3.1% — a meaningful income component for investors willing to look through near-term GAAP noise.
Bottom Line
Merck’s Q1 2026 results tell two parallel stories. The GAAP income statement shows a company in apparent distress — a $4.2 billion loss, a tripling of R&D expense, a dramatic reversal from a year-ago $5 billion profit. But beneath the charges, the operational picture is stable-to-positive: revenue growing 5%, Winrevair hitting its stride, Keytruda still driving oncology leadership, and management confident enough to raise the full-year bar. The Terns acquisition is a costly but deliberate bet on the post-Keytruda era. Whether that bet pays off will depend on whether the pipeline delivers — but the quarterly fundamentals, at least, are holding up.
Disclosure: This article was produced with AI assistance and reviewed before publication. It is for informational purposes only and is not investment advice.